Literature DB >> 23127390

Computed tomography-based sizing recommendations for transcatheter aortic valve replacement with balloon-expandable valves: Comparison with transesophageal echocardiography and rationale for implementation in a prospective trial.

Alexander B Willson1, John G Webb, Melanie Freeman, David A Wood, Ronen Gurvitch, Christopher R Thompson, Robert R Moss, Stefan Toggweiler, Ronnie K Binder, Bradley Munt, Anson Cheung, Cameron Hague, Jian Ye, Jonathon A Leipsic.   

Abstract

BACKGROUND: Computed tomography (CT) annular measurements are predictive of paravalvular regurgitation after transcatheter aortic valve replacement (TAVR) which is a predictor of mortality and morbidity.
OBJECTIVES: To demonstrate the rationale and potential implications of new CT sizing recommendations for TAVR.
METHODS: The CT sizing recommendations aim to ensure routine transcatheter heart valve (THV) oversizing of the aortic annular area [(THV external area/systolic annular area - 1) × 100; range, 1%-20%; target, 10%-15%]. Consecutive patients (n = 120) underwent CT before TAVR with balloon-expandable valves sized by transesophageal echocardiography (TEE). Retrospectively, the CT-recommended THV size was compared with the actual size implanted.
RESULTS: Compared with TEE, application of the newly developed CT-based sizing recommendations would have led to implantation of a larger valve in 33.3% (40/120), no change in valve size in 55.8% (67/120), and a smaller valve in 10.8% (13/120). In patients when CT recommended a larger valve, the incidence of at least moderate paravalvular regurgitation was 25% (10/40) compared with 4.5% (3/67; P < 0.01) when both TEE and CT recommendations were in agreement. Using diastolic versus systolic CT measurements results in 20% of patients receiving smaller THVs. TEE sizing resulted in 33.3% (40/120) of valves being undersized (THV area < CT systolic annular area) with a mean annular oversizing of 9.4% ± 17.4% (range: -21.5% to 65.9%) without annular rupture. In contrast, the CT sizing recommendations results in mean annular oversizing of 13.9% ± 8.0% (range, 1.3%-29.8%).
CONCLUSION: These CT sizing recommendations enable standardized moderate overexpansion of the aortic annulus. Clinical outcomes from these recommendations are being prospectively assessed in a multicenter trial.
Copyright © 2012 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23127390     DOI: 10.1016/j.jcct.2012.10.002

Source DB:  PubMed          Journal:  J Cardiovasc Comput Tomogr        ISSN: 1876-861X


  23 in total

1.  CT evaluation prior to transapical aortic valve replacement: semi-automatic versus manual image segmentation.

Authors:  Borek Foldyna; Camelia Jungert; Christian Luecke; Konstantin von Aspern; Sonja Boehmer-Lasthaus; Eva Maria Rueth; Matthias Grothoff; Stefan Nitzsche; Matthias Gutberlet; Friedrich Wilhelm Mohr; Lukas Lehmkuhl
Journal:  Int J Cardiovasc Imaging       Date:  2015-04-19       Impact factor: 2.357

2.  Temporal trends in transcatheter aortic valve implantation, 2008-2014: patient characteristics, procedural issues, and clinical outcome.

Authors:  Uri Landes; Alon Barsheshet; Ariel Finkelstein; Victor Guetta; Abid Assali; Amir Halkin; Hanna Vaknin-Assa; Amit Segev; Tamir Bental; Jeremy Ben-Shoshan; Israel M Barbash; Ran Kornowski
Journal:  Clin Cardiol       Date:  2016-10-26       Impact factor: 2.882

3.  Comparison of aortic root dimension changes during cardiac cycle between the patients with and without aortic valve calcification using ECG-gated 64-slice and dual-source 256-slice computed tomography scanners: results of a multicenter study.

Authors:  Abbas Arjmand Shabestari; Ramin Pourghorban; Mahmood Tehrai; Hamidreza Pouraliakbar; Taraneh Faghihi Langroudi; Hooman Bakhshandeh; Seifollah Abdi
Journal:  Int J Cardiovasc Imaging       Date:  2013-04-13       Impact factor: 2.357

Review 4.  Multidetector Computed Tomography (MDCT) Angiography in the Pre-Procedural Assessment of Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Cihan Duran; Irfan Masood; Alper Duran; Luba Frank; Arsalan Saleem; Raja Muthupillai; Benjamin Y C Cheong
Journal:  Eurasian J Med       Date:  2020-02

Review 5.  Mechanisms and management of TAVR-related complications.

Authors:  Amir-Ali Fassa; Dominique Himbert; Alec Vahanian
Journal:  Nat Rev Cardiol       Date:  2013-10-08       Impact factor: 32.419

6.  Avoiding Coronary Occlusion and Root Rupture in TAVI - The Role of Pre-procedural Imaging and Prosthesis Selection.

Authors:  Marco Barbanti
Journal:  Interv Cardiol       Date:  2015-05

Review 7.  Vascular Imaging Before Transcatheter Aortic Valve Replacement (TAVR): Why and How?

Authors:  Damiano Caruso; Russell D Rosenberg; Carlo N De Cecco; Stefanie Mangold; Julian L Wichmann; Akos Varga-Szemes; Daniel H Steinberg; Andrea Laghi; U Joseph Schoepf
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

8.  Performance of Dynamic Automated CT Annular Measurements Compared to Standard Manual Measurements for Transcatheter Aortic Valve Replacement Sizing.

Authors:  Quynh A Truong; Alan C Legasto; Roderick C Deaño; Daniel P Bachman; Deep Bhatt; Subhi J Al'Aref; Richard B Devereux; S Chiu Wong; Arash Salemi; Jackie Szymonifka
Journal:  Radiol Cardiothorac Imaging       Date:  2019-08-29

9.  Two-dimensional transesophageal echocardiography for aortic annular sizing in patients undergoing transcatheter aortic valve implantation.

Authors:  Mohammad A Sherif; Hüseyin Ince; Octavian Maniuc; Therese Reiter; Wolfram Voelker; Georg Ertl; Alper Öner
Journal:  BMC Cardiovasc Disord       Date:  2015-12-29       Impact factor: 2.298

10.  Feasibility of a new method using two-dimensional transesophageal echocardiography for aortic annular sizing in patients undergoing transcatheter aortic valve implantation; a case-control study.

Authors:  Mohammad A Sherif; Joerg Herold; Wolfram Voelker; Octavian Maniuc; Georg Ertl; Christian Praast; Ruediger Christian Braun-Dullaeus
Journal:  BMC Cardiovasc Disord       Date:  2015-07-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.